Healthcare Roundup – Qiagen to launch rapid COVID-19 blood test, Guardant Health gets U.S. emergency use nod for coronavirus test  

医疗保健精选——Qiagen启动COVID-19血液快检测试,Guardant Health新冠试剂获得美国紧急使用授权
Published on: August 24, 2020
Author: Amy Liu

Qiagen to launch rapid COVID-19 blood test in U.S.

QIAGEN (NYSE:QGEN) announces the U.S. launch of its Access Anti-SARS-CoV-2 Total test for the detection of SARS-CoV-2 antibodies in serum or plasma.

The rapid 10-minute assay is performed on the portable eHub digital device that can process up to 32 tests per hour.

Find the Next Tesla or SpaceX!  The GCFF Virtual Conference 2020 – Investing in Innovation, held on September 10, 2020, will connect Chinese investors living throughout North America to the latest investment opportunities in the fast growing innovative sectors of technology, clean technology, healthcare, life science, fintech and cannabis.  Hosted by NAI Interactive Ltd., the bilingual online event will feature 12 public and private company investment opportunities and will broadcast in English and Mandarin Chinese.

Registrations for The GCFF Virtual Conference 2020 – Investing in Innovation are free.  For more information and to register, please visit:

The company says the test has 100% sensitivity (correctly identifying true positives) and 100% specificity (correctly identifying true negatives).

Guardant Health gets U.S. emergency use nod for coronavirus test

The FDA has granted emergency use authorization (EUA) to Guardant Health’s (GH +0.3%) Guardant-19 test for use in the detection of the SARS-CoV-2 virus.

The test is a reverse transcriptase polymerase chain reaction next-generation sequencing test, that detects the coronavirus from upper respiratory nasal specimens. It has a validated limit of detection of 125 copies per mL and results are typically returned the next day.

The company says its testing workflow can be scaled to over 10,000 tests per day.

Amedisys inks agreement with BrightStar Care

Amedisys (NASDAQ:AMED) signed a Care Coordination Agreement with BrightStar Care in order to add its agencies to the Amedisys Personal Care Network and facilitate the coordination of care between the former’s hospice and home health care centers and personal care partners network.

BrightStar Care’s 340 personal care locations in 38 states covers ~75% of the U.S. population and largely overlaps Amedisys’ hospice and home health footprints; expands network to 1,211+ partner agencies in 39 states.

The new partnership will pilot with BrightStar care centers in Pennsylvania and Texas, with expansion plans later.

COVID-19 vaccine-stoked buying pressures antibody developers

On cue, the rally in several of the leading COVID-19 vaccine players on reports that the Trump administration is pushing hard for early emergency use authorization is pressuring antibody treatment developers on the perception that the availability of a vaccine will dampen demand for treatments.

Selected tickers: Gilead Sciences (GILD -0.7%) (antiviral treatment remdesivir), Vir Biotechnology (VIR -11.0%), Regeneron Pharmaceuticals (REGN -2.0%), Eli Lilly (LLY -0.2%)

Moderna in late-stage talks in Europe to supply COVID-19 vaccine

Moderna (NASDAQ:MRNA) confirms that it is in advanced discussions with the European Commission on an agreement to supply 80M doses of its COVID-19 vaccine, currently dubbed mRNA-1273. The deal will include the option to buy 80M additional doses.

It is scaling production aimed at delivering ~500M doses/year, with an upside of 1B doses annually, in 2021 (note that this is a run rate so the actual number of doses delivered next year will be less).

Shares up 1% premarket on modest volume.

Biotechnology Healthcare Services Life Science Medical Device Pharmaceutical